Prosecution Insights
Last updated: April 19, 2026
Application No. 17/786,764

INHIBITORS OF LIN28 AND METHODS OF USE THEREOF

Non-Final OA §102
Filed
Jun 17, 2022
Examiner
BAUER, NICOLA MARIA
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
3y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
25 granted / 42 resolved
-0.5% vs TC avg
Strong +47% interview lift
Without
With
+46.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
37 currently pending
Career history
79
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
48.2%
+8.2% vs TC avg
§102
22.5%
-17.5% vs TC avg
§112
10.0%
-30.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 42 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1, 2, 4, 9, 10, 12, 16, 17, 19, 21, 22, 27, 28, 33, 35, 48, 56, 79, 85 and 92 are pending. Claims 10, 17, 19, 21, 28, 33, 85 and 92 are withdrawn. Priority Applicant’s claim for benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. This application is a national stage entry of and claims priority to Application Serial No. PCT/US20/64896, filed 12/14/2020; and further claims priority to provisional application 62/949,873, filed 12/18/2019. Information Disclosure Statement All references from IDS(s) received 07/08/2022, 01/04/2024, 04/24/2024, 05/31/2024, 01/17/2025, and 11/03/2025 have been considered unless marked with a strikethrough. Election/Restrictions Applicant’s election of Group I without traverse in the reply filed on 11/03/2025 is acknowledged. Claims 85 and 92 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected method of use, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 11/03/2025. Applicant’s election of the compound below without traverse in the reply filed on 11/03/2025 is acknowledged. PNG media_image1.png 120 235 media_image1.png Greyscale Claims 10, 17, 19, 21, 28, and 33 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as not reading on the elected species. No anticipatory art was found of the elected specie, so the Examiner expanded her scope pursuant to MPEP 803. The expanded species are described in the 102 rejections. See 102 analysis below. Claims 1, 2, 4, 9, 12, 16, 22, 27, 35, 48, 56, and 79 will be examined upon their merits. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 2, 4, 9, 12, 16, 22, 27, 35, 48, 56, and 79 are rejected under 35 U.S.C. 102(a)(1)/(2) as being anticipated by Lau, W. (WO2017044623A1; cited in IDS filed 07/08/2022; “Lau”). This rejection applies to the expanded specie, the 15th compound of instant claim 56. PNG media_image2.png 114 175 media_image2.png Greyscale Lau teaches an overlapping genus structure with the instant claims. More specifically, Lau teaches structural example of the expanded specie, see below. PNG media_image3.png 192 243 media_image3.png Greyscale (Lau, Compound 339, Table 2) Therefore, Lau anticipates all the claims that the expanded specie reads on, including 1, 2, 4, 9, 12, 16, 22, 27, 35, 48, 56, and 79. Claims 1, 2, 4, 9, 22, 27, 35, 48, 56, and 79 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Albright, J. et al. (J. Med. Chem. 1981, 24, 5; cited in IDS filed 07/08/2022; “Albright”). This rejection applies to the expanded specie, the 34th compound of instant claim 56. PNG media_image4.png 80 179 media_image4.png Greyscale Albright teaches an overlapping genus structure with the instant claims. PNG media_image5.png 73 195 media_image5.png Greyscale (Table I) More specifically, Albright teaches an example of the expanded specie, see below. PNG media_image6.png 68 708 media_image6.png Greyscale Therefore, Albright anticipates all the claims that the expanded specie reads on, including 1, 2, 4, 9, 22, 27, 35, 48, 56, and 79. Conclusion Claims 1, 2, 4, 9, 12, 16, 22, 27, 35, 48, 56, and 79 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NICOLA MARIA BAUER whose telephone number is (703)756-1269. The examiner can normally be reached Monday-Friday 7:30-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clint Brooks can be reached at (571) 270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /N.M.B./Examiner, Art Unit 1621 /CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jun 17, 2022
Application Filed
Jan 30, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600726
ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
2y 5m to grant Granted Apr 14, 2026
Patent 12595273
PHOSPHONATE CONJUGATES AND USES THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12570612
SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF
2y 5m to grant Granted Mar 10, 2026
Patent 12565511
SOS1 INHIBITOR CONTAINING PHOSPHORUS
2y 5m to grant Granted Mar 03, 2026
Patent 12544324
HIGH CONCENTRATION VITAMIN C TOPICAL COMPOSITIONS AND METHOD OF MAKING SAME
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+46.8%)
3y 9m
Median Time to Grant
Low
PTA Risk
Based on 42 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month